MILAN, May 6, 2011 /PRNewswire/ — BD Diagnostics, a segment of
BD (Becton, Dickinson and Company) (NYSE:
BDX), today announced the European launch of the BD MAX™
Open System for molecular testing, which will enable laboratories
to run both laboratory and BD- developed assays and offer enhanced
testing services that elevate the standards of care at their
institutions.
BD made the launch announcement on the opening day of the 21st
European Congress of Clinical Microbiology and Infectious Diseases
and the 27th International Congress of Chemotherapy (ECCMID/ICC) in
Milan, Italy.
“In a world with ever-evolving pathogens, laboratories need to
provide clinicians with fast, accurate and actionable diagnostic
information that will save patient lives,” said Tom Polen,
President of BD Diagnostics – Diagnostic Systems. “The new
completely open, state-of-the-art BD MAX System empowers
laboratories to automate their unique internally developed
molecular assays, while accessing a rich and growing menu of
world-class assays from BD and our leading assay development
partners.”
BD MAX is the first and only fully automated, open, bench-top
molecular testing workstation able to perform both IVD/CE and
laboratory-developed tests. The BD MAX System gives clinical
laboratory professionals new ability to help their institutions
respond to emerging threats, such as new strains of deadly
drug-resistant bacteria or respiratory illnesses.
“BD’s strategy is to make BD MAX the laboratory equivalent of a
smartphone,” said Polen. “We are working with leading assay
development companies from around the world to develop a constantly
growing, content-rich menu of tests that deliver critical
information to caregivers faster and more accurately than current
methods. Our plan is to make the BD MAX System an indispensible
tool that no laboratory professional will want
‘/>”/>
SOURCE
